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Abstract
Background
Perfluoroalkyl substances (PFASs) have been associated with decreased immunity to child-
hood tetanus and diphtheria immunizations. If these vaccinations are vulnerable to influence
from PFASs, questions arise about associations with other common inoculations.
Objective
To examine whether serum PFASs were associated with reduced immunity to rubella immu-
nization, and whether interactions with sex or ethnicity warranted analytic stratification.
Usually, toxicology analyses are calculated controlling for race and sex. However, sex differ-
ences in immune function have been reported and a reduction of immunity to rubella in
women could pose risks such miscarriage.
Methods
We analyzed a nationally representative sample of individuals 12 years from the National
Health and Nutrition Examination Survey (NHANES) for years 1999–2000 and 2003–2004
for whom PFAS measures were available. Our analytic strategy was to start with separate
analyses for youth and adults controlling for several covariates including ethnicity and sex,
as well as the interaction of these terms with PFASs. If there was a main effect of PFASs
and an interaction term, we would stratify analyses of effect size. The outcome variable was
Rubella IgG titers by quartile of perfluoroalkyl substances.
Results
After exclusion for missing data, the analyzed sample contained 581 adult women, 621
adult men, and 1012 youth. There was no significant effect of PFASs on immunity in youths
but a significant effect of both PFOA and PFOS in adults, as well as a significant interaction
of PFOA x sex and a borderline significant interaction of PFOS x sex. When effect size anal-
yses were stratified by sex, a significant association between rubella titres and PFOA was
found in men but not women and PFOS was not significant in either sex.
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Conclusions
These results support our earlier studies showing sex specific responses to PFASs and indi-
cate the importance of thinking carefully about analytic strategies in population based toxi-
cology research.
Introduction
Perfluoroalkyl substances (PFASs), which include perfluorooctanoic acid (PFOA) and per-
fluorooctane sulfonate (PFOS), are synthetic compounds used in fluoropolymer synthesis.
These compounds are important in the manufacture of many fire resistant, stain resistant, and
non-stick products [1]. Concern about human exposure to these chemicals has increased due
to findings of their ubiquity and persistence in the environment [2–4] as well as their presence
in detectable amounts in over 98% of blood samples from a representative sample of the U. S.
population [5–6]. PFASs can be ingested from food and contaminated water [7], and seem to
be transferred through the placenta during pregnancy [8–9]. Exposure to these chemicals has
been linked to liver, lung, and kidney damage as well as to immune changes in rats [10] and
mice, [11–13] at concentrations similar to those found in humans [14]. In vitro studies using
human cell lines have also shown that PFASs suppress natural killer cell activity and cytokine
release [15–16]. More importantly, recent studies in humans suggest an association between
PFAS exposure and decreased immune response to vaccination. In a prospective cohort study
of children ages 5 and 7 years, it was reported that increased exposure to PFASs was associated
with decreased humoral immune response to childhood tetanus and diphtheria immuniza-
tions [17]. Another prospective cohort study found that increasing maternal PFAS levels were
associated with decreased rubella antibody titers in their children at age 3 [18]. In an adult
cohort from a PFOA contamination area it was found that increased PFOA exposure was asso-
ciated with reduced immune response to influenza vaccination and an increased risk of not
meeting the antibody threshold needed for long-term protection [19].
Despite these data, the mechanism through which PFASs might modulate the immune sys-
tem are still unknown, although there are suggestions of an association with the peroxisome
proliferator activated receptor alpha (PPAR alpha) [20]. It is also not known whether other
childhood immunizations may be affected by PFAS exposure or whether immune responses in
a typical adult are affected. The objective of this paper was to test whether the rubella titres of
MMR (measles-mumps-rubella) immunization are vulnerable to influence from PFAS expo-
sure in adults and youth. To do this we analyzed NHANES data, a nationally representative
sample that measured not only PFASs but also rubella titres. Rubella seemed an important
outcome to measure because it causes ‘3-day measles’, which can have the devastating conse-
quence of miscarriage in pregnant women. The relevance of this question is particularly
important to pregnant women who have been vaccinated and believe themselves to be resistant
[21].
Traditionally, toxicology analyses are very often calculated by controlling for the effect of
ethnicity and sex, despite the lack of any clear justification for doing this. The authors have
found sex specific physiological responses associated with PFASs in their earlier work [2]
but have not examined ethnicity differences. Based on previously published data showing
lower PFAS concentrations in menstruating women [22–26] that may be as great as 30% or
more [25–26], the hypothesis of this paper was that sex is an effect modifier and that by not
stratifying analyses, there is a risk that overall results will mask true associations. Given the
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importance that a reduction of immunity to rubella in women might pose, this seemed espe-
cially important to test.
Materials and methods
Participants
We analyzed merged data from the 1999–2000 and 2003–2004 cycles of the National Health
and Nutrition Examination Survey (NHANES). In brief, the NHANES survey includes a strati-
fied, cross-sectional, multistage probability sample representative of the civilian non-institu-
tionalized U.S. population. The sample is structured so that in principle, everyone in the U.S.
has an equal probability of being selected, and there is oversampling of low-income persons,
those 60 years of age or older, African Americans, and Mexican Americans to provide stable
estimates for these groups. These particular survey years were chosen because the survey
included biomonitoring for PFASs by the National Center for Environmental Health in a ran-
dom subsample of a third of the participants.
Detailed descriptions of the NHANES study design and methods are described elsewhere
[27]. Because the NHANES cohort changes with every iteration, these data are cross-sectional,
not prospective. Subjects were required to sign a consent form before participation, and
approval was obtained from the Human Subjects Committee of the US Department of Health
and Human Services. The data analyzed in this study were anonymized public use data avail-
able on the NHANES website.
Our sample consisted of NHANES participants 12 years of age or older for whom measure-
ments were available. There were 1387 adults (19–49), of whom 1202 had data available for
PFASs, rubella, and ethnicity and were not pregnant at the time of measurement (87%). Data
on young children was not available. Youth were defined as the age group ranging from 12 to
18 years. The resulting participants were 621 adult men, 581 adult women and 1012 youth.
Race / ethnicity was a designated classification in the NHANES dataset.
Rubella IgG titers
In NHANES 1999–2000 and 2003–2004 blood specimens were processed, stored and shipped
to Viral and Rickettsial Disease Laboratory, California State Department of Health Services,
Berkeley, California for analysis. The laboratory procedures for determining rubella IgG titer
are outlined in the Laboratory Procedure Manual: Measles, Rubella, and Varicella-Zoster Anti-
bodies [27]. Rubella titer values were log-transformed due to the skewness of their distribution.
Rubella was also classified as protective or non-protective titer; a rubella titer of10 IU is con-
sidered protective [28]. Preliminary analyses showed that most of the participants were above
this threshold (e.g., 94% of adults and 90% of youth), Seropositivity is a measure of clinical risk
but is not a proxy for whether or not someone has been vaccinated [28]. We were concerned
that excluding anyone under this threshold might bias our analyses by excluding those individ-
uals most affected by the endocrine disruption of PFASs. Therefore, all of whom were included
in the analyses.
PFOS and PFOA
Rigorous procedures and quality-control were used in blood collection and details about these
procedures are available in the NHANES Laboratory Procedures Manual [27]. PFOS and
PFOA were measured in serum of participants by the National Center for Environmental
Health, using automated solid-phase extraction coupled with isotope dilution high-perfor-
mance liquid chromatography-tandem mass spectrometry. Details of laboratory methods have
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been published previously [5]. The limits of detection were 0.1 ng/mL for PFOA and 0.2 ng/
mL for PFOS, and the interassay coefficients of variation were 11% for PFOA and 13% for
PFOS.
Covariates
Age, race/ethnicity, and educational level (high school, less than high school, more than high
school) were assessed using the demographic questionnaire. BMI was calculated as weight in
kilograms divided by height in meters squared. This covariate was included because earlier
work summarized by Knox et al. [2] showed that PFOA may vary in obese subjects, leading to
their analyzing the data in that paper by BMI. They found inconsistent results and we believe
that including it as a covariate was warranted. Because literature suggests that pregnancy and
birth impact PFASs levels, such that the higher the number of births the lower the mothers’
PFAS concentration [8], parity was assessed using the reproductive health questionnaire and
controlled for in the analyses in women. For these analyses, parity was defined in the dataset as
the number of live births. Although stillbirths might also have resulted in loss of PFASs, that
data was not available. This was also warranted because the dichotomous variable of having
or not having a child in this particular sample is associated with rubella titer. In women, the
number of live births was included as a covariate because it was associated with PFAS levels
(women lose PFASs with blood). Education was not included as a covariate in the youth analy-
ses because it is linearly associated with age.
Statistical approach
Earlier research has reported sex differences in the biological effects of PFASs [2], as well as sex
[29] and racial [30] differences in humoral immunity. Our earlier research [2, 8] and that of
others indicates that circulating PFAS levels in pregnant women and women who have given
birth are lower than those of non-pregnant women who have never given birth. The probable
reason is that these chemicals, which are otherwise bioacumulative, are transferred to the fetus
during gestation [8]. Women also lose PFASs with menstrual blood. However, this does not
mean that the association with Rubella titres is influenced by sex. Given earlier significant
results of PFASs on serum vaccine antibodies in children [17], we believed that the most logical
analytic strategy would be to start by calculating separate analyses in youth and adults. An
additional reason is that adult women differ from youth in ways that influence PFAS concen-
trations. In both age groups (12–18, and 19–60), we calculated the main effect of PFASs on
Rubella titres controlling for the covariates, age, BMI, educational level, sex, ethnicity and the
interactions of sex and ethnicity with PFASs. If no significant main effect of PFASs on Rubella
titres was found, we would report negative results and not massage the data by doing further
analyses. The point of including interaction terms (with sex and ethnicity) was to investigate
whether stratified analyses were justified. Earlier studies on PFASs from our group [1, 2, 31]
have found sex specific responses to PFASs to be the rule rather than the exception. If signifi-
cant main effects of PFASs were found, and there were significant interactions of sex or ethnic-
ity with PFASs, we would analyze the data further, stratifying according to the interaction that
was significant. The goal was not to compare men to women or ethnicities to one another, but
to assess the effect of PFASs on Rubella within group to assure that highly significant effects in
one sex /ethnicity group had not generalized to all. Quartiles of PFASs were calculated sepa-
rately in adults and youth.
Preliminary analyses of the current NHANES dataset, indicated that the ‘yes’ / ‘no’ response
to whether or not the respondent had children was significantly associated with rubella titer
and that the continuous variable (number of children) was significantly associated with PFOA
Rubella immunity and serum PFAS
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concentrations. For these reasons and because of the transfer of PFASs to the fetus during
pregnancy indicated by earlier work from our group [8], we also made the decision to control
for parity in women, should stratification by sex be indicated.
Thus, in the initial analyses we simply fitted multivariable linear regression models sepa-
rately for the effect of PFOA and PFOS quartiles (treated as categorical variables) of rubella
titres in adults and youth, adjusting for age, BMI, ethnicity, education, as well as interactions
of sex and ethnicity with PFASs. These analyses were essentially preliminary analyses to inves-
tigate whether there was any effect of PFASs on rubella titres and to see whether tests for
effect size should be stratified by either sex or ethnicity. Sex had a binary code (0, 1) so a signif-
icance in this variable indicated an effect of sex. Analyses were calculated with Proc Surveyreg,
SAS version 9.3 to account for survey weights and design (SAS Institute, Inc., Cary, North
Carolina).
Results
Descriptive statistics
Table 1 presents the characteristics of the study population. Approximately 37% of the sample
were non-Hispanic white men, 6% non-Hispanic black men, and 9% Hispanic. Percentages
were similar in women. About twenty-three percent of the youth in this cohort were non-His-
panic white, 31% non-Hispanic black, and 42% Hispanic. About 49% were female and 44% of
adults lived in households where the highest level of education was more than a high school
education. The average PFOA concentration was about 6 ng/mL (standard error ± 0.3) in
men, 4.3 ng/mL in women and 4.8 ng/mL in youth. Sex differences in adults were significant.
The average PFOS concentration in men was 28.1 ng/mL (standard error ± 0.7), 22.1 ng/mL in
women and 25.1 in youth.
Whole group analyses—Youth
Whole group linear regression analyses of youth (12–18 years) showed no significant associa-
tions with Rubella titres for either PFOA or PFOS adjusting for covariates, nor were there
Table 1. Descriptive statistics (rounded to the nearest decimal).
Men Pr. Women Youth (12–18)
Age (mean ± SE) 34.3 ± 0.7 .0001 35.2 ± 0.7 15.0 ± 0.6
BMI (mean ± SE) 28.0 ± 0.3 .0001 28.5 ± 0.5 23.8 ± 0.2
PFOS ng/mL (mean ± SE) 28.1 ± 1.3 .0001 22.1 ± 0.9 25.1 ± 0.4
PFOA ng/mL (mean ± SE) 6.0± 0.3 .0001 4.3 ± 0.2 4.8 ± 0.7
Rubella Titer IU (mean ± SE) 74.7.± 3.4 .001 69.3 ± 2.7 52.8 ± 2.4
Race/ethnicity % 0.44 %
Non-Hispanic White (%) 36.6 35.1 22.9
Non-Hispanic Black (%) 5.6 6.7 30.9
Mexican American/ Hispanic (%) 8.5 7.5 41.6
Education 0.42
Less Than High School (%) 8.2 8.5 35.1
High School Grad/GED/Equival (%) 15.4 12.7 21.7
More Than High School (%) 27.0 28.3 39.2
P-value for significance set at 0.05. Analyses separated by sex in adults due to a significant interaction between sex and PFASs
https://doi.org/10.1371/journal.pone.0203330.t001
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interactions of PFASs with sex or ethnicity. The results can be seen in Table 2. Thus, in adher-
ence with our analytic strategy, we did not stratify or analyze this group any further.
Whole group analyses—Adults
In adults, there was a significant association between both PFOA (p = 0.0016) and PFOS
(p = 0.0295) quartiles and rubella titers after controlling for covariates (sex, age, ethnicity, edu-
cation, BMI and the interactions between sex and PFOA and ethnicity and PFOA). Interac-
tions between sex and PFOA were significant (p = 0.0193) but with PFOS only borderline
significant (0.0609) in adults. These can be seen in Table 3.
Due to the significant sex x PFOA interaction and borderline significant PFOS interaction,
we stratified the subsequent analyses for estimates and confidence intervals by sex, fitting
Table 2. Youth.
Effect (N = 1196) F Value Pr > F
PFOA
PFOA quartile 0.34 0.7974
Sex 0.31 0.5828
Ethnicity 14.47 <.0001
SexPFOA quartile 0.32 0.8088
EthnicPFOA quartile 0.68 0.6637
PFOS
PFOS Quartile 1.44 0.2512
Sex 0.27 0.6045
Ethnicity 18.59 <.0001
SexPFOS quartile 0.88 0.4631
EthnicPFOS quartile 1.33 0.2742
Regression analyses of log rubella titres on PFOA and PFOS quartiles adjusted for age, sex, educational level,
ethnicity, BMI and sex/ethnicity interaction terms.
https://doi.org/10.1371/journal.pone.0203330.t002
Table 3. Adults.
Effect (N = 1193) F Value Pr > F
PFOA
PFOA Quartile 6.60 0.0016
Sex 3.50 0.0716
Ethnicity 4.21 0.0249
Sex  PFOA quartile 3.86 0.0193
Ethnic  PFOA quartile 1.92 0.1117
PFOS
PFOS Quartile 3.44 0.0295
Sex 1.82 0.1883
Ethnicity 3.74 0.0359
Sex  PFOS quartile 2.75 0.0609
Ethnic  PFOS quartile 0.89 0.5179
Regression analyses of log rubella titres on PFOA and PFOS quartiles adjusted for age, gender, ethnicity, BMI,
educational level and sex/ ethnicity interaction terms.
https://doi.org/10.1371/journal.pone.0203330.t003
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multivariable linear regression models to calculate and compare log rubella IgG titer for each
quartile of PFOS and PFOA. The lowest quartile was used as the referent.
Analyses stratified by sex
There were no significant associations between rubella titres and either PFOA or PFOA con-
centrations in women. In men, only PFOA showed significant negative associations with
rubella titres, indicating that the higher the PFOA, the lower the Rubella titre. The closest
PFOS came to significance in men was p = 0.08 between the second and first quartiles. The
PFAS data for both men and women can be seen in Table 4.
Discussion
When men and women were analyzed together, controlling for sex and ethnicity, both PFOA
and PFOS showed significant associations with rubella titre. The interaction for sex x PFOA
was highly significant, whereas the interaction of sex with PFOS was only borderline. In analy-
ses stratified by sex, PFOA showed significant negative associations with rubella titres only in
men. One quartile of PFOS was also borderline significant in men. This illustrates that a strong
value in only one sex can carry over into an overall significance for the whole group when sex
is adjusted for in the analyses, leaving the reader with incorrect conclusions about risk. Table 1
shows that the differences in levels of rubella titres between men and women are significant.
This apparent discrepancy could be partly due to the previously mentioned sex differences
related to menstrual cycles [22–26] and parity. If women have lower concentrations of PFASs
to begin with, it may explain why the subsequent stratified analyses controlling for parity in
women show a more pronounced effect of PFOA than PFOS on rubella titres in men.
Previous findings
Unlike previous findings associated with tetanus, diphtheria immunity [17], this study does
not show immune system effects of PFASs in youth, however, the children in the earlier study,
Table 4. Adult analyses stratified by sex.
WOMEN MEN
Effect
(N = 542)
Estimate Pr > T Confidence
Intervals
Effect
(N = 613)
Estimate Pr > T Confidence
Intervals
PFOA
Quartile
PFOA
Quartile
Quartile 1 0.0000 Quartile 1 0.0000
Quartile 2 -0.2536 0.0636 -0.52, 0.02 Quartile 2 - 0.1382 0.3387 -0.43, 0.15
Quartile 3 -0.1495 0.6856 -0.90, 0.60 Quartile 3 -0.5477 0.0002 -0.81, -0.28
Quartile 4 -0.1658 0.6769 -0.97, 0.64 Quartile 4 -0.4450 0.0278 -0.84, -0.05
PFOS
Quartile
PFOS
Quartile
Quartile 1 0.000 Quartile 1 0.0000
Quartile 2 0.0450 0.81 -0.34, 0.43 Quartile 2 -0.1987 0.35 -0.62, 0.23
Quartile 3 0.0439 0.87 -0.51, 0.60 Quartile 3 -0.3179 0.08 -0.69, 0.05
Quartile 4 -0.1664 0.73 -1.13, 0.80 Quartile 4 0.0086 0.97 -0.54, 0.56
Regression analyses of log rubella titres on PFOA and PFOS quartiles adjusted for age, sex, ethnicity, BMI and educational level, as well as number of live births in
women (only in women because they lose PFASs with blood during delivery).
https://doi.org/10.1371/journal.pone.0203330.t004
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a Danish birth cohort, were under the age of 5, whereas our study included only youth between
12–18 years. The earlier study found that elevated PFAS exposure was associated with a
decreased humoral immune response and increased odds of having an antibody level below a
clinically protective level. As we had no children under 5 in our dataset we were unable to test
whether that age group might also be especially vulnerable to PFAS effects on rubella immu-
nity. However, a more recent study [32] also analyzed NHANES data, defining youth as ages
12–19 found a significant negative correlation between rubella titre and PFASs in the seroposi-
tive group only. It was also unclear to us why youths up to the age of 19 were classified as chil-
dren in that study and we chose to use the more common cutoff of 18. As to seropositivity,
there are multiple possible approaches. We chose not to do separate analyses for seropositive
and seronegative groups for the several reasons. Our earlier research and that of others [2, 8–
9] has shown that PFASs are endocrine disrupters and accumulating data support an associa-
tion between endocrine disruption and the immune system [33–35]. There is justification for
both approaches and we believe that this supports our contention that careful thought should
be given to analytic strategy due to its important consequences for interpretation of results.
Traditional toxicology analysis strategies
It has been traditional in toxicology analyses to use sex as a covariate in multivariable regres-
sion equations [17, 19]. We believe that for a number of reasons this can lead to misleading
interpretation of the data. First, a statistically large effect in one sex can generalize to the entire
group when analyses are adjusted for sex, making it look as if the effect is generalized across
all. Second, men and women are fundamentally different physiologically. This has been dem-
onstrated in our previous work with PFOA and PFOS [2, 8, 29].
The varying effect of PFAS exposure on immunity in men and women found in this study
is actually not surprising, not only because women have lower concentrations than men but
also because women are known to mount a more robust immune response to antigenic chal-
lenge than men. Women have shown increased antibody responses to many vaccines; mumps
[36–37], smallpox [38], influenza [39], and rubella [36, 40] when compared with men. With
respect to the influenza vaccine women have been found to respond to a half dose of vaccine
at comparable levels to men given a full dose [39]. The increased robustness of the immune
response in women may explain why they seemed to be less vulnerable to reduced rubella
immunity from PFAS exposure than men. It should also be noted that women have higher
rates of many autoimmune diseases [41]; scleroderma, Sjogren’s syndrome, rheumatoid arthri-
tis and systemic lupus erythematosus suggesting other sex related differences in immunity
Mediating mechanisms such as pharmacokinetics, receptor signaling and effect on immune
cells require further research.
Limitations
The main limitation of this study is that NHANES data is cross-sectional and therefore the tem-
poral nature of the association between PFASs and humoral immune response could not be
determined. We also did not have young children in this cohort. There are other factors that
might have influenced rubella titres that were not available for examination. There was no infor-
mation concerning whether the participants had actually been vaccinated or had had rubella
infection which could influence seropositivity. There was also no information as to the age at
which vaccination occurred, other infections, or variation in vaccination rates and schedules.,
Despite the caveats, we believe that these data indicate caution in the way toxicology data
are analyzed and a preference for stratifying by rather than controlling for sex. A clear ratio-
nale for analytic strategies should be included in reports.
Rubella immunity and serum PFAS
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Conclusions
Our findings suggest that there are sex specific responses in the immunity to rubella associated
with PFAS exposure and that it is important to include examination of sex x exposure interac-
tions when analyzing immune responses to potentially toxic agents.
Acknowledgments
The authors would like to thank Matthew Gurka, PhD, for mentoring Ms. Pilkerton in the ini-
tial analysis of the data. We would also like to thank Jie Xiao, MS, for work helping to merge,
clean and define the variables of the NHANES data.
Author Contributions
Conceptualization: Sarah S. Knox.
Formal analysis: Gerald R. Hobbs, Christa Lilly, Sarah S. Knox.
Methodology: Gerald R. Hobbs, Sarah S. Knox.
Supervision: Sarah S. Knox.
Writing – original draft: Courtney S. Pilkerton.
References
1. Frisbee SJ, Shankar A, Knox SS, Steenland K, Savitz DA, Fletcher T,. Perfluorooctanoic acid, perfluor-
ooctanesulfonate, and serum lipids in cildren and adolescents: results from the C8 Health Project. Arch
Pediatr Adoles Med 2010; 164:860–869.
2. Knox SS, Jackson T, Frisbee SJ, Javins B, Ducatman AM. Perfluorocarbon exposure, gender and thy-
roid function in the C8 Health Project. J Toxicol Sci 2011; 36;403–410. PMID: 21804304
3. Lin C-Y, Chen P-C, Lin Y-C, Lin L-Y. Association among serum perfluoroalkyl chemicals, glucose
homeostasis, and metabolic syndrome in adolescents and adults. Diabetes Care 2009; 32:702–707.
https://doi.org/10.2337/dc08-1816 PMID: 19114613
4. Melzer D, Rice N, Depledge MH, Henley WE, Galloway TS. Association between serum perfluoroocta-
noic acid (pfoa) and thyroid disease in the us national health and nutrition examination survey. Environ
Health Perspect 2010; 118:686. https://doi.org/10.1289/ehp.0901584 PMID: 20089479
5. Calafat AM, Wong L-Y, Kuklenyik Z, Reidy JA, Needham LL. 2007. Polyfluoroalkyl chemicals in the us
population: Data from the national health and nutrition examination survey (nhanes) 2003–2004 and
comparisons with nhanes 1999–2000. Environm Health Perspectives 2007: 115:1596–1602.
6. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. Perfluoroalkyl acids: A review of moni-
toring and toxicological findings. Toxicol Sci 2007; 99:366–394. https://doi.org/10.1093/toxsci/kfm128
PMID: 17519394
7. Vestergren R, Cousins IT. 2009. Tracking the pathways of human exposure to perfluorocarboxylates.
Environmental science & technology 43:5565–5575.
8. Javins B, Hobbs G, Ducatman AM, Pilkerton C, Tacker D, Knox SS. Circulating maternal perfluoroalkyl
substances during pregnancy in the c8 health study. Environ Science & Technol 2013 47:1606–1613.
9. Needham LL, Grandjean P, Heinzow B, Jørgensen PJ, Nielsen F, Patterson DG Jr, et al. Partition of
environmental chemicals between maternal and fetal blood and tissues. Environ Sci & Technol 2010;
45:1121–1126.
10. Cui L, Zhou Q-f, Liao C-y, Fu J-j, Jiang G-b. Studies on the toxicological effects of pfoa and pfos on rats
using histological observation and chemical analysis. Arch Environ Contam Toxicol 2009; 56:338–349.
https://doi.org/10.1007/s00244-008-9194-6 PMID: 18661093
11. Dong G-H, Zhang Y-H, Zheng L, Liu W, Jin Y-H, He Q-C. Chronic effects of perfluorooctanesulfonate
exposure on immunotoxicity in adult male c57bl/6 mice. Arch toxicol 2009; 83:805–815. https://doi.org/
10.1007/s00204-009-0424-0 PMID: 19343326
12. Peden-Adams MM, EuDaly JG, Dabra S, EuDaly A, Heesemann L, Smythe J, et al. Suppression of
humoral immunity following exposure to the perfluorinated insecticide sulfluramid. J Toxicol & Environ
Health, 2007. Part A 70:1130–1141.
Rubella immunity and serum PFAS
PLOS ONE | https://doi.org/10.1371/journal.pone.0203330 September 24, 2018 9 / 11
13. Peden-Adams MM, Keller JM, EuDaly JG, Berger J, Gilkeson GS, Keil DE. Suppression of humoral
immunity in mice following exposure to perfluorooctane sulfonate. Toxicoll Sci 2008; 104:144–154.
14. Fair PA, Driscoll E, Mollenhauer MAM, Bradshaw SG, Yun SH, Kannan K, et al. Effects of environmen-
tally-relevant levels of perfluorooctane sulfonate on clinical parameters and immunological functions in
B6C3F1 mice. J Immunotoxicol 2011; 8:Iss. 1.
15. Brieger A, Bienefeld N, Hasan R, Goerlich R, Haase H. 2011. Impact of perfluorooctanesulfonate and
perfluorooctanoic acid on human peripheral leukocytes. Toxicol in Vitro 25:960–968. https://doi.org/10.
1016/j.tiv.2011.03.005 PMID: 21397682
16. Corsini E, Avogadro A, Galbiati V, Marinovich M, Galli CL, Germolec DR. In vitro evaluation of the
immunotoxic potential of perfluorinated compounds (pfcs). Toxicol Appl Pharmacol 2011; 250:108–116.
https://doi.org/10.1016/j.taap.2010.11.004 PMID: 21075133
17. Grandjean P, Andersen EW, Budtz-Jørgensen E, Nielsen F, Mølbak K, Weihe P, et al. Serum vaccine
antibody concentrations in children exposed to perfluorinated compounds. JAMA: 2012; 307:391–397.
https://doi.org/10.1001/jama.2011.2034 PMID: 22274686
18. Granum B, Haug LS, Namork E, Stølevik SB, Thomsen C, Aaberge IS, et al. Pre-natal exposure to per-
fluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related
health outcomes in early childhood. J Immunotox 2013; 10:373–379.
19. Looker C, Luster MI, Calafat AM, Johnson VJ, Burleson GR, Burleson FG, et al. 2014. Influenza vaccine
response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate. Toxicol Sci 2014;
138:76–88. https://doi.org/10.1093/toxsci/kft269 PMID: 24284791
20. DeWitt JC, Shnyra A, Badr MZ, Loveless SE, Hoban D, Frame SR, et al. Immunotoxicity of perfluorooc-
tanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor
alpha. Critical Rev Toxicol 2009; 39:76–94.
21. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. 1998. Measles, mumps, and rubella-vaccine
use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of
mumps: Recommendations of the Advisory Committee on Immunization Practices (acip). 1998;47 (no.
Rr-8.DTIC) Document.
22. Harda K, Inue K, Morikawa A, Yoshinaga T, Saito N, Koizumi a. Renal clearance of perfluorooctane sul-
fonate and perfulorooctanoate in humans and their species-specific excretion. Environ Res 2005;
99:253–361. https://doi.org/10.1016/j.envres.2004.12.003 PMID: 16194675
23. Lorber M, Eaglesham GE, Hobson P, Toms L-ML, Mueller JF, Thompson JS. The effect of ongoing
blood loss on human serum concenteraations of perfluorinated acids. Chemosphere 2015; 118:170–
177. https://doi.org/10.1016/j.chemosphere.2014.07.093 PMID: 25180653
24. Li Y, Mucs D, Scott K, Lindh C, Tallving P, Fletcher T, Technical Report: No 2:2017. Half-lives of PFOS,
PFHxS and PFOA after end of exposure to contaminated drinking water. The Sahlgrenska Academy
Institute of Medicine, Go¨teborgs Universitet.
25. Wong F, MacLeod M, Mueller JF, Cousins IT. Enhanced elimination of perfluorooctane sulfonic acid by
menstruating women: Evidence from population-based pharmacokinetic modeling. Environ Sci Technol
2014, 48:8807–8814. https://doi.org/10.1021/es500796y PMID: 24943117
26. Verner M-A, Longnecker MP. Comment on “Enhanced elimination of perfluorooctanesulfonic acid by
menstruating women: Evidence from popoulatioin-based pharmacokinetic modeling. Environ Sci Tech-
nol 2015; 49:5836–5837. https://doi.org/10.1021/acs.est.5b00187 PMID: 25871968
27. Centers for Disease Control and Prevention. 2014. National health and nutrition examination survey.
http://www.cdc.gov/nchs/nhanes/about_nhanes.htm.
28. Skendzel LP. Rubella immunity. Defining the level of protective antibody. Am J Clin Pathol 1996;
106:170–174. PMID: 8712168
29. Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008; 26:3551–3555.
https://doi.org/10.1016/j.vaccine.2008.04.054 PMID: 18524433
30. Buckley C, Dorsey F. Serum immunoglobulin levels throughout the life-span of healthy men. Ann Inter
Med 1971; 75:673–682.
31. Knox SS, Jackson T, Javins B, Frisbee SJ, Shankar A, Ducatman AM. Implications of early menopause
in women exposed to perfluorocarbons. J Clin Endocrin & Metabol 2011; 96:1747–1753.
32. Stein CR, McGovern KJ, Pajak AM, Magilione PJ, Wolff MS. Perfluoroalkyl and polyfluoroalkyl sut-
stances and indicatoars of immune function in children aged 12–19 years: NHANES. Pediatr Res 2016;
79:348–357.
33. Chalubinski M, Kowalski ML. Endocrine disrupters–potential modulators of the immune system and
allergic response. Allergy 2006; 61:1326–1335. https://doi.org/10.1111/j.1398-9995.2006.01135.x
PMID: 17002710
Rubella immunity and serum PFAS
PLOS ONE | https://doi.org/10.1371/journal.pone.0203330 September 24, 2018 10 / 11
34. Milla S, Depiereux S, Kestemont P. the effects of estrogenic and androgenic endocrine disrupters on
the immune system of fish: a review. Ecotoxicology 2011; 20:305–319. https://doi.org/10.1007/s10646-
010-0588-7 PMID: 21210218
35. Jin Y, Chen R, Liu W, Fu Z. Effect of endocrine disrupting chemicals on the transcription of genes
related to the innate immune sytem in the early developmental stage of zebrafish (Danio rerio). Fish &
Shellfish Immun 2010; 10:854–861.
36. Dhiman N, Ovsyannikova IG, Vierkant RA, Pankratz V, Jacobson RM, Poland GA. Associations
between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to mea-
sles, mumps and rubella in a somali population. Tissue Antigens 2008; 72:211–220. https://doi.org/10.
1111/j.1399-0039.2008.01097.x PMID: 18715339
37. Ovsyannikova IG, Jacobson RM, Dhiman N, Vierkant RA, Pankratz VS, Poland GA. Human leukocyte
antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses
to mumps viral vaccine. Pediatrics 2008 121:e1091–e1099. https://doi.org/10.1542/peds.2007-1575
PMID: 18450852
38. Kennedy RB, Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Ryan MA, et al. Gender
effects on humoral immune responses to smallpox vaccine. Vaccine 2009; 27:3319–3323. https://doi.
org/10.1016/j.vaccine.2009.01.086 PMID: 19200827
39. Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang C-Y, Cox NJ, et al. Half-vs full-dose trivalent
inactivated influenza vaccine (2004–2005): Age, dose, and sex effects on immune responses. Arch
Inter Med 2008; 168:2405.
40. Mitchell LA, Zhang T, Tingle AJ. The Journal of Infectious Diseases 1992; 166:1258–1265.
41. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmunity Reviews 2003;
2:119–125. PMID: 12848952
Rubella immunity and serum PFAS
PLOS ONE | https://doi.org/10.1371/journal.pone.0203330 September 24, 2018 11 / 11
